File Archive - Nicotine Addiction Documents - Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge (2007)

News Groups Blog Forum Chat Video Audio Images Documents Wiki Home

		Drugs Forum > File Archive > Documents > VARIOUS DRUG RELATED TOPICS > Addiction Documents > Nicotine Addiction Documents
Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge (2007)

Tags

FAQ n Rules

Mark Forums Read

Notices

Create a FREE account now to get access to more forums, more videos, more music, more documents, more images, more reviews, more news about drugs and much more functionality.
Start posting now, join our groups or create your unique profile.

links

Nicotine Addiction Documents

Documents about Nicotine Addiction and Dependence

New entries announced in forum Recovery and addiction

Allowances: 4.88 Mbytes/1.49 Mbytes used

[RSS Feed]

Entries

Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge (2007)

Left click: open entry/Right click: save entry

Tobacco Control 2007 Apr;16(2):138-42

Kotlyar M, Mendoza-Baumgart MI, Li ZZ, Pentel PR, Barnett BC, Feuer RM, Smith EA, Hatsukami DK.

OBJECTIVE: To compare nicotine pharmacokinetics and subjective effects of three new smokeless tobacco potential reduced exposure products (PREPs; Ariva, Revel and Stonewall) with moist snuff (Copenhagen) and medicinal nicotine (Commit lozenge). METHODS: 10 subjects completed a randomised, within-subject, crossover study. Subjects used one product for 30 min at each of the five laboratory sessions. Maximal nicotine concentration (Cmax) was determined and area under the concentration time curve (AUC) was calculated for a 90-min period (during use and 60 min after use). Nicotine craving, withdrawal symptoms and ratings of product effects and liking were measured during product use. RESULTS: Nicotine AUC and Cmax were higher for Copenhagen than for any other product (p<0.002) and higher for Commit than for either Ariva or Revel (p<0.001). Cmax for Commit was also higher than for Stonewall (p = 0.03). Craving was lowest during use of Copenhagen (p<0.03). Craving during use of Stonewall, Ariva and Commit was lower than during use of Revel (p<0.05). Withdrawal symptom score during use of Copenhagen was lower than during use of Revel (p = 0.009). Copenhagen scores were higher (p<0.005) than all other products in several measures of drug effects and liking (feel good effects, satisfaction, liking and desire for product, and strength of product). CONCLUSION: The new smokeless tobacco PREPs result in lower nicotine concentrations and equivalent or lower reductions in subjective measures compared with medicinal nicotine. Since health effects of PREPs are largely unknown, medicinal nicotine should be preferentially encouraged for smokers or smokeless tobacco users wishing to switch to lower-risk products.

Discussion Thread

Category Nicotine Addiction Documents

Submitted by Jatelka

05-09-2008
291.16 Kbytes Hits 5

Category

Forum Jump

Sitelinks:	Site Functions:
Homepage Wiki Documents Image Gallery Audio Video Forum Blog Groups News	Site Rules Frequently Asked Questions Register to Participate Did you forget your password? All Threads

All times are GMT +1. The time now is 17:44.